Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Foghorn Therapeutics Inc (Foghorn) is a clinical-stage biotechnology company that develops medicines that treat serious diseases by correcting abnormal gene expression. The company pipeline products including FHD-909 (LY4050784, Selective SMARCA2) for SMARCA4 ,mutated cancers including non-small cell lung cancer, bladder, endometrial and colorectal cancer; Selective EP300 treats dependent cancers and CBP mutated cancers includes non-small cell lung cancer, bladder cancer and melanoma; and Selective ARID1B targets ARID1A mutated cancers include all solid tumors; among others. Its proprietary Gene Traffic Control platform is a powerful tool for understanding and modulating the chromatin regulatory system. Foghorn is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
Suite 700, 500 Technology Square, Cambridge, Massachusetts, 02139
Website
www.foghorntx.com
Telephone
1 617 5863100
No of Employees
112
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
FHTX (NASD)
Revenue (2024)
$22.6M
-33.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
12%
(2024 vs 2023)
Market Cap*
$327.0M
Net Profit Margin (2024)
XYZ
-33.0%
(2024 vs 2023)
* As of and is in US$
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Gene Traffic Control |
| FHD-909 (LY4050784, Selective SMARCA2):SMARCA4 Mutated Cancers (Non-Small Cell Lung Cancer, Bladder, Endometrial and Colorectal Cancer) | |
| Selective EP300: Dependent Cancers and CBP Mutated Cancers (non-Small Cell Lung Cancer, Bladder Cancer and Melanoma) | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Foghorn Therapeutics Inc | Novartis AG | Arvinas Inc | Ideaya Biosciences Inc | Nurix Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | United States of America | United States of America |
| City | Cambridge | Basel | New Haven | South San Francisco | Brisbane |
| State/Province | Massachusetts | Basel-Stadt | Connecticut | California | California |
| No. of Employees | 112 | 75,883 | 430 | 145 | 317 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael Mendelsohn, M.D | Chairman | Executive Board | 2017 | - |
| Adrian Gottschalk | Chief Executive Officer; Director; President | Executive Board | 2004 | 49 |
| Ryan Maynard | Chief Financial Officer | Senior Management | 2026 | - |
| Michael LaCascia | Chief Legal Officer | Senior Management | 2020 | 61 |
| Carlos Costa | Chief People Officer | Senior Management | 2022 | 52 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer